Article Text

PDF
Cohort study
Intussusception risk increased after rotavirus vaccination but outweighed by benefits
  1. Evan J Anderson1,2,
  2. Bethany K Sederdahl1
  1. 1Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA
  2. 2Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
  1. Correspondence to : Dr Evan J Anderson, Departments of Pediatrics, Emory University School of Medicine, 2015 Uppergate Drive, Atlanta, GA 30322, USA; evanderson{at}emory.edu

Statistics from Altmetric.com

Commentary on: OpenUrlCrossRefPubMedWeb of Science OpenUrlCrossRefPubMedWeb of Science

Context

Prior to the introduction of paediatric rotavirus vaccination, rotavirus was the most common cause of infectious gastroenteritis to result in the hospitalisation of children and accounted for about 450 000 deaths in children per year worldwide.1 Use of the first rotavirus vaccine, RotaShield (Wyeth Lederle), was discontinued within 1 year of US licensure after intussusception was identified in about 1 of every 10 000 children within 2 weeks of vaccination.2

Two new rotavirus vaccines, RotaTeq (RV5, Merck) and Rotarix (RV1, GlaxoSmithKline), when assessed in prelicensure studies of >60 000 infants were not associated with an increased risk of intussusception. Since US licensure of RV5 in 2006 and RV1 in 2008, these vaccines have been carefully monitored for safety. Postlicensure studies in Mexico, Brazil and Australia have identified a relationship between …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.